The Kinetics of Angiotensin-I Metabolism in Human Carotid Atheroma: An Emerging Role for Angiotensin (1–7)
Nehmea et al., Vascular Pharmacology (2016) – PMID: 27497910
Product(s) used in this publication: Reference Peptides for Targeted Proteomics - SpikeTides™ & SpikeMix™
Abstract:
AIM:
Local levels of angiotensin peptides depend on their rates of production and degradation, which induce proatherogenic or atheroprotective effects. Here, we reveal the kinetics of Angiotensin-Imetabolism in paired early and advanced atherosclerotic lesions.
METHODS:
Lesions were spiked with labeled Ang-I* and supernatants withdrawn after 0, 10, 20, 40 and 80min. The concentration of produced Ang-II*, Ang-III*, Ang-IV* and Ang-(1-7)* peptides were measured using multiple reaction monitoring mass spectrometry coupled to ultra-performance liquid chromatography, normalized to tissue weight and initial [Ang-I*].
RESULTS:
Ang-(1-7)* was the major angiotensin peptide produced, showing increased levels in both tissue types, with 2-3 fold lower levels in advanced compared to early lesions. In contrast, Ang-II* was 2-3 fold higher in advanced compared to early lesions, showing a decrease between 0 and 40min then an increase at 80min in both tissue types. The levels of Ang-IV were stable in both tissue types across all time points. Finally, Ang-III was non-detectable in both lesions across all time points.
CONCLUSION:
Our results suggest that progression of atherosclerosis depends on the increased levels of Ang-II along with the decreased levels of Ang-(1-7), which supports the use of Ang-(1-7) along with Angiotensin type-1 receptor (AT1R) blockers.
Copyright © 2016 Elsevier Inc. All rights reserved.
KEYWORDS:
Angiotensin; Atherosclerosis; Mass spectrometry; Metabolism; Renin-angiotensin-aldosterone system